Loading...
•
Mar 30, 2024
USANA Q1 2024 Earnings Report
USANA's financial performance was affected by strength in mainland China operations, offsetting softness in other markets facing inflationary pressures.
Key Takeaways
USANA Health Sciences reported a decrease in net sales and diluted EPS for Q1 2024 compared to Q1 2023. Net sales were $228 million, and diluted EPS was $0.86. The company is reiterating its fiscal year 2024 net sales and diluted EPS outlook.
First quarter net sales were $228 million, an 8% decrease compared to Q1 2023.
First quarter diluted EPS was $0.86, a 9% decrease compared to Q1 2023.
Active Customers increased 1% compared to Q1 2023, totaling 494,000.
The company reiterates fiscal year 2024 net sales and diluted EPS outlook of $850 million to $920 million and $2.40 to $3.00.
Revenue by Geographic Location
Forward Guidance
The Company is reiterating its net sales and earnings per share outlook for fiscal year 2024, as follows: Consolidated Net Sales $850 - $920 million and Diluted EPS $2.40 - $3.00.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...